Five novel N‐substituted demethylvancomycin derivatives were rationally designed and synthesized by using a structure‐based approach. The in vitro antibacterial activities against methicillin‐resistant Staphylococcus aureus (MRSA), gentamicin‐resistant Enterococcus faecalis (GRE), methicillin‐resistant Streptococcus pneumoniae (MRS), and vancomycin‐resistant Enterococcus faecalis (VRE) were evaluated. One of the compounds, N‐(6‐phenylheptyl)demethylvancomycin (12 a), was found to exhibit more potent antibacterial activity than vancomycin and demethylvancomycin. Compound 12 a was also found to be ∼18‐fold more efficacious than vancomycin against MRSA; however, the two compounds were found to have similar efficacy against MRS. Furthermore, compound 12 a exhibited a favorable pharmacokinetic profile with a half‐life of 5.11±0.52 h, which is longer than that of vancomycin (4.3±1.9 h). These results suggest that 12 a is a promising antibacterial drug candidate for further preclinical evaluation.

中文翻译：

---

去甲基万古霉素类似物的设计，合成及其对耐药细菌的抗菌活性

通过使用基于结构的方法，合理设计和合成了五种新颖的N-取代的脱甲基万古霉素衍生物。评估了对耐甲氧西林金黄色葡萄球菌（MRSA），耐庆大霉素的粪便肠球菌（GRE），耐甲氧西林的肺炎链球菌（MRS）和耐万古霉素的粪便肠球菌（VRE）的体外抗菌活性。发现其中一种化合物N-（6-苯基庚基）脱甲基万古霉素（12 a）比万古霉素和脱甲基万古霉素显示出更强的抗菌活性。化合物12 a还发现抗MRSA的效力比万古霉素高约18倍；但是，发现这两种化合物对MRS的疗效相似。此外，化合物12中的表现出有利的药物动力学轮廓具有5.11±0.52小时的半衰期，这比万古霉素（4.3±1.9 H）的长。这些结果表明12 a是用于进一步临床前评估的有希望的抗菌药物候选物。